公开(公告)号：US11981679B2

公开(公告)日：2024-05-14

申请号：US17884493

申请日：2022-08-09

申请人： IMPETIS BIOSCIENCES LTD.

发明人： Sujay Basu ,  Sachin Thorat ,  Yogesh Shejul ,  Anil Panmand ,  Meena Patel ,  Goraksha Khose ,  Rajesh Bonagiri ,  Dinesh Barawkar ,  Bheemashankar Kulkarni ,  Kasim Mookhtiar

IPC分类号： C07D487/14

CPC分类号： C07D487/14

摘要： The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them.

D-A-B—Z  (I)

Formula I

公开(公告)号：US11407758B2

公开(公告)日：2022-08-09

申请号：US16959543

申请日：2019-01-04

申请人： IMPETIS BIOSCIENCES LTD.

发明人： Sujay Basu ,  Sachin Thorat ,  Yogesh Shejul ,  Anil Panmand ,  Meena Patel ,  Goraksha Khose ,  Rajesh Bonagiri ,  Dinesh Barawkar ,  Bheemashankar Kulkarni ,  Kasim Mookhtiar

IPC分类号： C07D487/14

摘要： The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).